Jan Lötvall Explained
Jan Lötvall (also spelled Lotvall) is a Swedish clinical allergist and scientist working on translational research primarily in the field of asthma. He is the former director of the Krefting Research Centre at the University of Gothenburg[1] and is the Chief Scientific Officer of ExoCoBio.[2] [3]
Lötvall's laboratory proposed extracellular vesicles such as exosomes and microvesicles as shuttles of RNA molecules between cells[4] along with several other groups in 2006,[5] 2007,[6] and 2008.[7]
Lötvall was a member of the Executive Committee of the European Academy of Allergy and Clinical Immunology, its secretary general from 2005 to 2009, and its president from June 2009 to June 2011.[8] Lötvall was also co-editor-in-chief of Respiratory Research from 2003 to 2018.[9] He was the first president of the International Society for Extracellular Vesicles (2012–2016) and chaired the first society meeting in Gothenburg, in April 2012.[10] Lötvall became Editor-in-Chief of Journal of Extracellular Vesicles in 2019.
Lötvall studied medicine at the Karolinska Institutet in Stockholm (1981–1985) and graduated from the Medical School of the University of Gothenburg in 1987. He became interested in asthma research in the mid-1980s. After studying as a visiting fellow at the National Heart and Lung Institute, London from 1988 to 1990), Lötvall defended his thesis in February, 1991. He trained in both pharmacology and allergology, and became a specialist in these areas in 1997 and 1999, respectively. He became associate professor (docent) at the University of Gothenburg in 1993 and full professor of clinical allergology in 2002. He is currently Chief Scientific Officer of ExoCoBio.[11] [12]
Notes and References
- Web site: Krefting Steering Committee - Krefting Research Centre, University of Gothenburg, Sweden . 2011-01-03.
- Web site: ExoCoBio website.
- Web site: ExoCoBio's First Global Regenerative Aesthetic Exosome Summit. 2024-01-15.
- Valadi H, Ekström K, Bossios A, Sjöstrand M, Lee JJ, Lötvall JO . Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells . . 9 . 6 . 654–9 . June 2007 . 17486113 . 10.1038/ncb1596 . 8599814 .
- 16283305 . 2006 . Baj-Krzyworzeka . M. . Szatanek . R. . Weglarczyk . K. . Baran . J. . Urbanowicz . B. . Brański . P. . Ratajczak . M. Z. . Zembala . M. . Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes . Cancer Immunology, Immunotherapy . 55 . 7 . 808–818 . 10.1007/s00262-005-0075-9 . 25723677 . 11030663 .
- 17556595 . 2007 . Aliotta . J. M. . Sanchez-Guijo . F. M. . Dooner . G. J. . Johnson . K. W. . Dooner . M. S. . Greer . K. A. . Greer . D. . Pimentel . J. . Kolankiewicz . L. M. . Puente . N. . Faradyan . S. . Ferland . P. . Bearer . E. L. . Passero . M. A. . Adedi . M. . Colvin . G. A. . Quesenberry . P. J. . Alteration of marrow cell gene expression, protein production, and engraftment into lung by lung-derived microvesicles: A novel mechanism for phenotype modulation . Stem Cells . 25 . 9 . 2245–2256 . 10.1634/stemcells.2007-0128 . 3376082 .
- Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, Curry WT Jr, Carter BS, Krichevsky AM, Breakefield XO . Glioblastoma microvesicles . . 10 . 12 . 1470–6 . Dec 2008 . 19011622 . 10.1038/ncb1800 . 3423894 .
- Web site: Executive Committee . European Academy of Allergy and Clinical Immunology . 2011-01-03.
- Lotvall J, Panettieri Jr RA . 2018 . Thank you and farewell after 15 years editing Respiratory Research . . 19 . 232 . 232 . 10.1186/s12931-018-0929-2 . 30477500 . 6258390 . free .
- Web site: Executive Board (2012-2014) | ISEV - International Society for Extracellular Vesicles . ISEV . 2012-10-08 . dead . https://web.archive.org/web/20130805015720/http://www.isev.org/node/17 . 2013-08-05 .
- Web site: ExoCoBio website.
- Web site: ExoCoBio's First Global Regenerative Aesthetic Exosome Summit. 2024-01-15.